碳化硼还原法制备LaB6的提纯

采用碳化硼还原法制备LaB6.为了提高LaB6的纯度,先将原料碳化硼进行化学处理,再用其还原氧化镧,并经酸洗、蒸馏水洗等步骤制备出Fe含量低于0.01％、C含量低于0.02％的LaB6粉末.整个工艺过程LaB6的收率为79.5％.     

硅钼蓝分光光度法测定六硼化镧中酸溶硅的研究

LaB6经稀硝酸分解,在0．1mol／L硫酸介质中,正硅酸与钼酸铵生成黄色的硅钼杂多酸,提高硫酸浓度至1．2mol／L以消除磷、砷的干扰,用抗坏血酸将硅钼黄还原成硅钼蓝,考察了分光光度法的最大吸收波长为660nm;该方法适宜于LaB6中硅含量的测定;加标回收率及精密度实验都符合实验要求。     

稀土La对粉末冶金钛合金组织和力学性能的影响

在Ti-Fe-Mo合金中以LaH2和LaB6两种形式引入稀土La,制备含La的粉末冶金钛合金,研究La的添加量对钛合金烧结行为以及组织与力学性能的影响,探讨合金中La的存在形式及其在烧结过程中的作用机理。结果表明,钛合金相对密度随LaH2添加量(质量分数)的增加而升高,当LaH2的添加量达到0.6%后,钛合金的相对密度不再发生明显变化;但随着LaB6添加量的增加先升高后降低,在LaB6添加量为0.15%时出现峰值。添加LaH2的钛合金中,稀土元素主要以La2O3颗粒的形式存在,随La含量增加,颗粒发生长大;而在添加LaB6的合金中,烧结反应产物主要是纤维状的TiB、具有规则外形的La2O3颗粒以及含Ti和O的富La絮状颗粒。随LaH2和LaB6的添加量增加,合金的室温抗拉强度和伸长率均先升高后降低。LaH2的添加量达到0.6%时出现强度峰值,添加量达到0.3%时出现伸长率的峰值;而LaB6的添加量达到0.15%时抗拉强度和伸长率均出现峰值。     

等离子发射光谱法测定六硼化镧中铁、钙、镁、铬、锰、铜

采用等离子发射光谱法测定六硼化镧中铁、钙、镁、铬、锰、铜,各元素测定范围：0．0001％～0．10％,方法回收率在91．0％～110％;相对偏差小于10％。方法准确度高,精密度好,结果令人满意。     

CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles

CYP2D6 genotyping (CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*13, CYP2D6*16 alleles and gene duplications) was previously performed on 1053 Caucasian and African-American lung cancer cases and control individuals and no significant difference in allele frequencies between cases and control individuals detected. We have carried out additional genotyping (CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*17 alleles) and debrisoquine phenotyping on subgroups from this study to assess phenotype-genotype relationships. African-Americans showed significant differences from Caucasians with respect to frequency of defective CYP2D6 alleles, particularly CYP2D6*4 and CYP2D6*5. The CYP2D6*17 allele occurred at a frequency of 0.26 among 87 African-Americans and appeared to explain higher average metabolic ratios among African-Americans compared with Caucasians. CYP2D6*6, CYP2D6*8, CYP2D6*9 and CYP2D6*10 were rare in both ethnic groups but explained approximately 40% of higher than expected metabolic ratios among extensive metabolizers. Among individuals phenotyped with debrisoquine, 32 out of 359 were in the poor metabolizer range with 24 of these (75%) also showing two defective CYP2D6 alleles. Additional single strand conformational polymorphism analysis screening of samples showing large phenotype-genotype discrepancies resulted in the detection of three novel polymorphisms. If subjects taking potentially interfering drugs were excluded, this additional screening enabled the positive identification of 88% of phenotypic poor metabolizers by genotyping. This sensitivity was comparable with that of phenotyping, which identified 90% of those with two defective alleles as poor metabolizers.     

Novel glycoinositolphosphosphingolipids, basidiolipids, from Agaricus

From the edible mushroom, the basidiomycetes Agaricus bisporus and Agaricus campestris, a novel carbohydrate-homologous series of four glyco-inositol-phospho-sphingolipids, designated basidiolipids, was isolated and the constituents purified. The chemical structures of the basidiolipids were elucidated to be: Manpbeta1-2inositol1-phospho-ceramide, Galpalpha-6[Fucpalpha-2]Galpbeta-6Manpbeta-2i nositol1-phospho-ceramide, Galpalpha-6Galpalpha-6[Fucpalpha-2]Galpbeta- 6Manpbeta-2inositol1-phospho-ceramide and Galpalpha-6Galpalpha-6Galpalpha-6[Fucpalpha-2] Galpbeta-6Manpbeta-2ino sitol1-phospho-ceramide. All four glycolipids contained a ceramide which was composed of phytosphingosine and predominantly alpha-hydroxy-behenic and alpha-hydroxy-lignoceric acid.     

Apoptosis of Th1-like cells in experimental tuberculosis (TB)

A series of 2-amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine mono- and diesters, 6a-h, were synthesized as potential prodrugs of ganciclovir and evaluated for their oral ganciclovir bioavailability in rats. Treatment of 2-amino-6-chloro-9-(1, 3-dihydroxy-2-propoxymethyl)purine (4) with Me3N in DMF/THF (1/4) followed by the reaction of the resulting trimethylammonium chloride salt 5 with KF in DMF gave 2-amino-9-(1, 3-dihydroxy-2-propoxymethyl)-6-fluoropurine (2) in 83% yield. Esterification of 2 with an appropriate acid anhydride (Ac2O, (EtCO)2O, (n-PrCO)2O, or (i-PrCO)2O) (6 equiv for 6a-d or 1 equiv for 6e-h) in DMF in the presence of a catalytic amount of DMAP produced the diesters 6a-d in 92-98% yields and the monoesters 6e-h in 37-44% yields. Of the prodrugs tested in rats, the monoisobutyrate 6h achieved the highest ganciclovir bioavailability (45%) that is 15-fold higher than that from ganciclovir (3%), followed in order by the diisobutyrate 6d (42%), the diacetate 6a (41%), the monobutyrate 6g (41%), the monopropionate 6f (39%), the dipropionate 6b (35%), the dibutyrate 6c (35%), and the monoacetate 6e (29%). The prodrugs 6e-h were found to be quite stable at pH 6.0 (t1/2 = >29 days), 7.4 (t1/2 = >7 days), and 8.0 (t1/2 = >2 days) but had relatively short half-lives at pH 1.2 (t1/2 = 60-83 min).     

Electrochemical Behavior of Bulk Amorphous Steel Fe55M2Cr12Mo10B6C13Y2（M=Ni, Cu, Nb）

 Fe55Ni2Cr12Mo10B6C13Y2,Fe55Cu2Cr12Mo10B6C13Y2 and Fe55Nb2Cr12Mo10B6C13Y2 alloys with diameter of 4mm were produced by copper mold casting. The role of alloying additions (Ni, Cu or Nb) on corrosion resistance of Fe55Nb2Cr12Mo10B6C13Y2, Fe55Ni2Cr12Mo10B6C13Y2 and Fe55Cu2Cr12Mo10B6C13Y2 alloys were studied by polarization curves and electrochemical impedance spectroscopy (EIS). The results show that Fe55Ni2Cr12Mo10B6C13Y2 and Fe55Cu2Cr12Mo10B6C13Y2 alloys can be cast into bulk metallic glasses. Fe55Ni2Cr12Mo10B6C13Y2 and     

Electrochemical Behavior of Bulk Amorphous Steel Fe55M2Cr12Mo10B5C13Y2(M=Ni,Cu,Nb)

Fe55Ni2Cr12Mo10B6C13Y2,Fe55Cu2Cr12Mo10B6C13Y2 and Fe55Nb2Cr12Mo10B6C13Y2 alloys with diameter of 4 mm were produced by copper mold casting. The effect of alloying additions (Ni,Cu or Nb) on corrosion resistance of Fe55 Ni2 Cr2Mo10 B6 C13 Y2,Fe55Ni2Cr12Mo10B6C13Y2 and Fe55 Cu2 Cr12 Mo10 B6 C13 Y2 alloys was studied by polarization curves and electrochemical impedance spectroscopy (EIS). The results show that Fe55Ni2Cr12Mo10B6C13 Y2 and Fe55Cu2Cr12Mo10B6C13 Y2 alloys can be cast to form bulk metallic glasses. Fe55Ni2Cr12Mo10B6C13 Y2 and Fe55Cu2Cr12 Mo10B6C13Y2 amorphous alloys with passive potential about 1500 mV exhibit good corrosion resistance in NaCl solution of 5 % and 1 mol/L HC1 solution. The passive current density of the alloy with Ni addition is lower than that of other alloys. EIS results only show one impedance element. Amorphous alloy Fe55 Ni2 Cr12 Mo10 B6 C13 Y2 with larger charge transfer reaction resistance indicates good corrosion resistance.     

Studies on the constituents of Calliandra anomala (Kunth) Macbr. I. Structure elucidation of two acylated triterpenoidal saponins

Two novel triterpenoidal saponins, called calliandra saponins A and E, were isolated from the branches of Calliandra anomala (Kunth) Macbr. On the basis of the chemical and physiocochemical evidence, their structures were defined as 3-O-alpha-L-arabinopyranosyl-(1-->2)-alpha-L-arabinopyranosyl++ +-(1-->6)-2- acetamido-2-deoxy-beta-D-glucopyranosyl echinocystic acid 28-O-(beta-D-glucopyranosyl-(1-->3)-[beta-D-xylopyranosyl-(1-->3)-beta-D - xylopyranosyl-(1-->4)]-alpha-L-rhamnopyranosyl-(1-->2)-[(6S)-2-trans- 2,6-dimethyl-6-O-beta-D-xylopyranosyl-2,7-octadienoyl-(1-->6)]-bet a-D- glucopyranosyl) ester (4) and 3-O-alpha-L-arabinopyranosyl-(1-->2)-alpha-L-arabinopyranosyl++ +-(1-->6)-2- acetamido-2-deoxy-beta-D-glucopyranosyl echinocystic acid 28-O-[beta-D-glucopyranosyl-(1-->3)-[beta-D-xylopyranosyl-(1-->3)-beta-D - xylopyranosyl-(1-->4)]-alpha-L-rhamnopyranosyl-(1-->2)-[(6'S)-2'-trans- 2',6'-dimethyl-6'-O-(2-O-(6S)-2-trans-2,6-dimethyl-6-hydroxy-2,7-octa dienoyl)- beta-D-xylopyranosyl-2',7'-octadienoyl-(1-->6)]-beta-D-glucopyr ano syl] ester (5), respectively.     

Bi_2WO_6 doped with rare earth ions:Preparation,characterization and photocatalytic activity under simulated solar irradiation

Rare-earth modification Bi_2 WO_6 composites(RE/Bi_2 WO_6) were studied by experimental performance and theory computation based on the different 4 f orbits of selected rare earth elements(La,Ce,Gd,and Yb).The prepared RE/Bi_2 WO_6 was characterized by XRD,SEM/TEM,XPS,UV-vis DRS,and N_2 adsorption to learn their physical-chemical properties.Azo dye Rhodamine B(RhB) was photodegraded as a target pollutant to investigate the photocatalytic activity of prepared RE/Bi_2 WO_6 composites.The results of experiment and computation show that four rare earth elements with different electron configurations retain the phase and morphology of Bi_2 WO_6 and enhance the removal efficiency of RhB under simulated solar irradiation.The optimum doping contents are 0.01%,0.05%,0.05% and 0.01% for La-,Ce-,Gd-,and Yb-doped Bi_2 WO_6,respectively.However,light rare earth La and Ce doped composites indicate some difference in visible light adso rption capacity and mineralization on RhB co mpared with heavy rare earth Gd and Yb doped composites.Both La/Bi_2 WO_6 and Ce/Bi_2 WO_6 possess larger pore size and higher mineralization ability than Gd/Bi_2 WO_6 and Yb/Bi_2 WO_6 under the same experimental conditions while Gd/Bi_2 WO_6 and Yb/Bi_2 WO_6 show stronger red shift to the visible light due to the more 4 f electrons.The hole oxidation plays a major role in the photodegradation of RhB by all RE/Bi_2 WO_6.     

Identification and characterization of thionucleosides in the total tRNA of cucumber cotyledons

Total tRNA isolated from cucumber cotyledons grown in the presence of radioactive sulfur was analyzed for the occurrence of thionucleosides. The analysis revealed the presence of at least five thionucleosides which were identified as 5-methylaminomethyl-2-thiouridine (mnm5s2U), 2-methylthio-N6-isopentenyladenosine (ms2i6A), 2-methylthio-N6-hydroxyisopentenyladenosine (ms2io6A), 5-methyl-2-thiouridine (m5s2U) and N-[(9-beta-ribofuranosyl-2- methylthiopurine-2-yl)-carbamoyl]-threonine (ms2t6A). A comparison of relative amounts of these thionucleosides in the total tRNAs of dark-, and light-grown cotyledons shows that the relative amounts of ms2i6A, ms2io6A and ms2t6A remain unchanged whereas mnm5s2U increases with a concomitant decrease in the relative amounts of m5s2U after light treatment of dark-grown cotyledons.     

Stereoselectivity of the aliphatic hydroxylation of 6-n-propylchromone-2-carboxylic acid in rat and guinea pig

Following administration of 6-n-propylchromone-2-carboxylic acid (6-n-PCCA) (500 mumol/kg) to male rats, three metabolic products were detected and isolated from the 0-24 h urine. All were identified as resulting from oxidation exclusively along the 6-n-propyl moiety. Some 66% of the dose was excreted in the 0-24 h urine, 55% of which was 6-PCCA, with 15% as (6-1'-hydroxypropyl)chromone-2-carboxylic acid (6-1'-HPCCA), 22% as 6-(2'-hydroxypropyl)chromone-2-carboxylic acid (6-2'-HPCCA), and 4% as 6-3'-carboxypropyl)chromone-2-carboxylic acid (6-3'-CPCCA). Derivatization of the methyl esters of the hydroxylated metabolites with S-alpha-methoxy-alpha-(trifuloromethyl)-phenylacetyl chloride (Mosher's reagent) allowed the evaluation of urinary enantiomeric composition by HPLC and assignment of their absolute configurations by NMR. This was found to be 90:10 (R/S) for 6-2'-HPCCA, and 7:93 (R/S) for 6-1'-HPCCA. When rats were dosed with the racemic 1'- and 2-hydroxy metabolites; no stereoselective metabolism or excretion was observed. Administration of 6-n-PCCA to male guinea pigs revealed that this species was unable to metabolise this compound.     

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

The cytokines interleukin-2 (IL-2) and interleukin-6 (IL-6) increase during immune activation, they are released from activated astrocytes and microglial cells in the central nervous system (CNS), and they are able to enhance the catecholaminergic neurotransmission. This study focused on the soluble receptors of IL-2 and IL-6 (sIL-2R, sIL-6R) as a part of the regulation system of IL-2 and IL-6. We studied serum levels of sIL-2R in 30 schizophrenic patients not under neuroleptic medication during an acute exacerbation of the disease and reexamined these patients under neuroleptic treatment after clinical improvement. The sIL-6R levels of 39 schizophrenic patients were estimated under the same conditions. The results were compared with the levels of sIL-2R and sIL-6R in 42 healthy controls. No difference was found between the schizophrenic patients before neuroleptic treatment and the healthy controls. During neuroleptic treatment, however, there was a significant increase of sIL-2R levels and a significant decrease of the sIL-6R levels between the pre- and post-conditions. In comparison with healthy controls, the treatment group also showed increased sIL-2R levels and decreased sIL-6R levels. These results suggest that treatment with neuroleptics is associated with increased sIL-2R and decreased sIL-6R. Since sIL-2R bind and inactivate IL-2, whereas sIL-6R form an active complex with IL-6, the increase of sIL-2R and the decrease of sIL-6R together may reflect a functional down regulation of these activating cytokines. This suggests that neuroleptic therapy has a differentiated immunomodulatory effect.     

Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450

The effects of methanol, ethanol, dimethyl sulfoxide (DMSO), and acetonitrile were studied in vitro on nine individual, cDNAexpressed cytochrome P-450 activities (phenacetin O-deethylase for CYP1A1 and CYP1A2, coumarin 7-hydroxylase for CYP2A6, testosterone 6beta-hydroxylase for CYP3A4, 7-ethoxy-4-trifluoromethylcoumarin deethylase for CYP2B6, paclitaxel 6alpha-hydroxylase for CYP2C8, diclofenac 4'-hydroxylase for CYP2C9, S-mephenytoin 4-hydroxylase for CYP2C19, and (+/-)-bufuralol 1'-hydroxylase for CYP2D6) in commercially available human lymphoblastoid microsomes. These data show that specific solvents have enzyme-selective effects on P-450 activities. Methanol did not substantially inhibit (相似文献   

Prostaglandin E2 stimulates the production of interleukin-6 by neonatal mouse parietal bones

The pleiotropic cytokine interleukin-6 (IL-6) is thought to be involved in bone homeostasis. A number of bone resorbing agents have been shown to induce the release of IL-6 from bone. We wished to determine whether prostaglandin E2 (PGE2), which is a mediator of bone resorption, can elicit the production of IL-6. IL-6 was measured by the proliferative response of B9 hybridoma cells and could be completely neutralised by an anti-IL-6 antibody. Parietal bones from neonatal mice were maintained in culture in the presence of indomethacin (10(-6) M) with or without PGE2. The time course and dose-response to PGE2 of IL-6 production were determined. After 6 h in culture, 10(-8) M PGE2 produced significantly more IL-6 than the controls (P < 0.005). PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml). When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production. However, intact bones were required for maximal stimulated IL-6 production.     

Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism

The mutant of CYP2D6*3 allele with A2637 deletion in exon 5 and the mutant of CYP2D6*4 allele G1934-->A, splice site defect are among the most common polymorphic alleles of CYP2D6 gene, resulting in a decreased or no activity of CYP isoenzyme. In this study, a reliable polymerase chain reaction-restriction fragment length polymorphism method for identification of CYP2D6*3 and CYP2D6*4 alleles was used to investigate the genotype and phenotype prevalence in the groups of normal controls, and of cirrhosis and cancer patients. The results showed none of 36 controls genotyped for 2D6*3 and 2D6*4 allele to have the 2D6*3 allele with frameshift mutation in exon 5, while 33% (n=12) were found to bear the 2D6*4 allele with G to A mutation at the intron 3-exon 4 junction. In breast cancer patients (n=35) genotyped for 2D6*3 and 2D6*4 alleles, none with 2D6*3 allele was found either, but 60% (n=18) were found to bear the 2D6*4 allele. In patients with head and neck squamous cell cancer, there was only one subject with 2D6*3 allele and he was heterozygous. Among them, as many as ten (40%) patients were found to bear 2D6*4 allele. In the cirrhosis group, none of the patients was found to have the 2D6*3 allele, while the CYP2D6*4 allele was found in 23% (n=6) patients. The phenotype predicted according to the genotype was as follows: in the control group, 3% of individuals were identified as poor metabolizers, 70% as extensive metabolizers, and 27% as heterozygote extensive metabolizers. In the group of breast cancer, 7% of the patients were identified as poor metabolizer, 57% as extensive metabolizer and 36% as phenotype. In squamous cell cancer and cirrhosis patients, the incidence of poor metabolizer was zero, and of heterozygotes extensive metabolizer 42% and 31%, respectively.     

Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity

The cellular protein E6AP functions as an E3 ubiquitin protein ligase in the E6-dependent ubiquitination of p53. E6AP is a member of a family of functionally related E3 proteins that share a conserved carboxyl-terminal region called the Hect domain. Although several different E2 ubiquitin-conjugating enzymes have been shown to function with E6AP in the E6-dependent ubiquitination of p53 in vitro, the E2s that cooperate with E6AP in the ubiquitination of its normal substrates are presently unknown. Moreover, the basis of functional cooperativity between specific E2 and Hect E3 proteins has not yet been determined. Here we report the cloning of a new human E2, designated UbcH8, that was identified in a two-hybrid screen through specific interaction with E6AP. We demonstrate that UbcH7, an E2 closely related to UbcH8, can also bind to E6AP. The region of E6AP involved in complex formation with UbcH8 and UbcH7 was mapped to its Hect domain. Furthermore, we show that UbcH5 and UbcH6, two highly homologous E2s that were deficient for interaction with E6AP, could associate efficiently with another Hect-E3 protein, RSP5. Finally, only the E6AP-interacting E2s could function in conjunction with E6AP in the ubiquitination of an E6 independent substrate of E6AP, whereas the noninteracting E2s could not. Taken together, these studies demonstrate for the first time complex formation between specific human E2s and the Hect domain family of E3 proteins and suggest that selective physical interaction between E2 and E3 enzymes forms the basis of specificity for functionally distinct E2:E3 combinations.     

Primary palmar hyperhidrosis presenting with unilateral symptoms: a report of two cases and review of the literature

To further investigate the association between Parkinson's disease (PD) and genetic polymorphism of the CYP2D6 gene, a mutant allele (CVP2D6J) frequently observed in the Japanese population and related to EM/PM polymorphism (phenotypically, individuals are either extensive metabolizers [EM] or poor metabolizers [PM] of debrisoquine) was investigated. The CYP2D6J gene with a nucleotide substitution from C to T at position 188 (the HphI site in exon 1), which reduces CYP2D6 enzyme activity, was analyzed by polymerase chain reaction (PCR) and by digestion with HphI. No significant relationship was observed between PD patients and controls for this mutation. This suggests that the EM/PM polymorphism of CYP2D6 contributes little to the pathogenesis of PD. To further study the molecular basis for the relationship between PD and CYP2D6, the heterogeneity of CYP2D6 was investigated by combined genotype analysis of the two mutant CYP2D6 genes (ie, CYP2D6J, the HphI site mutation in exon 1, and CYP2D6L, the HhaI site mutation in exon 6). Although some characteristic patterns of the combined genotypes were observed in both PD patients and controls, a strong association between the heterogeneity of the CYP2D6 gene and PD was not shown by combined genotype analysis.